Welcome to LookChem.com Sign In|Join Free

CAS

  • or
N-Tosyl-4-bromo-2-iodo-7-azaindole is a chemical compound characterized by the molecular formula C13H9BrIN2O2S. It is a substituted azaindole derivative featuring a tosyl group attached to the nitrogen atom. Known for its biological activity, this compound holds promise for pharmaceutical research and drug development. The incorporation of bromine and iodine atoms in its structure enhances its potential utility in organic synthesis and as a building block for more complex chemical structures. Further research and testing are required to determine its specific properties and potential uses.

480423-17-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 480423-17-4 Structure
  • Basic information

    1. Product Name: N-Tosyl-4-bromo-2-iodo-7-azaindole
    2. Synonyms: N-Tosyl-4-bromo-2-iodo-7-azaindole;4-Bromo-2-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine;4-Bromo-2-iodo-N-tosyl-7-azaindole;1H-Pyrrolo[2,3-b]pyridine, 4-broMo-2-iodo-1-[(4-Methylphenyl)sulfonyl]-;4-bromo-2-iodo-1-tosyl-7-azaindole;4-Bromo-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
    3. CAS NO:480423-17-4
    4. Molecular Formula: C14H10BrIN2O2S
    5. Molecular Weight: 477.115
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 480423-17-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 574.6°C at 760 mmHg
    3. Flash Point: 301.3°C
    4. Appearance: /
    5. Density: 2g/cm3
    6. Vapor Pressure: 3.31E-13mmHg at 25°C
    7. Refractive Index: 1.743
    8. Storage Temp.: 2-8°C(protect from light)
    9. Solubility: N/A
    10. CAS DataBase Reference: N-Tosyl-4-bromo-2-iodo-7-azaindole(CAS DataBase Reference)
    11. NIST Chemistry Reference: N-Tosyl-4-bromo-2-iodo-7-azaindole(480423-17-4)
    12. EPA Substance Registry System: N-Tosyl-4-bromo-2-iodo-7-azaindole(480423-17-4)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 480423-17-4(Hazardous Substances Data)

480423-17-4 Usage

Uses

Used in Pharmaceutical Research and Drug Development:
N-Tosyl-4-bromo-2-iodo-7-azaindole is utilized as a key intermediate in the synthesis of pharmaceutical compounds due to its unique structure and biological activity. Its presence in the molecule allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
N-Tosyl-4-bromo-2-iodo-7-azaindole serves as a valuable building block in organic synthesis, enabling the creation of more complex chemical structures. The presence of bromine and iodine atoms facilitates various synthetic transformations, making it a versatile component in the synthesis of a wide range of organic compounds.
Used in Chemical Research:
N-Tosyl-4-bromo-2-iodo-7-azaindole is employed as a research tool in chemical studies, providing insights into the reactivity and properties of substituted azaindole derivatives. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic strategies.

Check Digit Verification of cas no

The CAS Registry Mumber 480423-17-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,0,4,2 and 3 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 480423-17:
(8*4)+(7*8)+(6*0)+(5*4)+(4*2)+(3*3)+(2*1)+(1*7)=134
134 % 10 = 4
So 480423-17-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H10BrIN2O2S/c1-9-2-4-10(5-3-9)21(19,20)18-13(16)8-11-12(15)6-7-17-14(11)18/h2-8H,1H3

480423-17-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-bromo-2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine

1.2 Other means of identification

Product number -
Other names 4-bromo-2-iodo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:480423-17-4 SDS

480423-17-4Relevant articles and documents

Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials

Mahindra, Amit,Janha, Omar,Mapesa, Kopano,Sanchez-Azqueta, Ana,Alam, Mahmood M.,Amambua-Ngwa, Alfred,Nwakanma, Davis C.,Tobin, Andrew B.,Jamieson, Andrew G.

supporting information, p. 9300 - 9315 (2020/10/19)

The protein kinase PfCLK3 plays a critical role in the regulation of malarial parasite RNA splicing and is essential for the survival of blood stage Plasmodium falciparum. We recently validated PfCLK3 as a drug target in malaria that offers prophylactic,

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

-

Paragraph 000552, (2019/11/04)

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles

Varnes, Jeffrey G.,McGuire, Thomas,Meadows, Rebecca E.,Barlaam, Bernard,Clark, Jemma,Cook, Calum R.,Davison, Gemma,Dishington, Allan,De Savi, Chris,Donald, Craig,Grebe, Tyler,Hande, Sudhir,Hawkins, Janet,Hird, Alexander W.,Holmes, Jane,Lister, Andrew,Lucas, Simon,Moore, Jane,Moore, Esther,Patel, Anil,Pike, Kurt G.,Roberts, Bryan,Stark, Andrew,Stead, Darren,Thakur, Kumar,Turner, Paul,Vasbinder, Melissa,Yang, Bin

supporting information, p. 4718 - 4722 (2016/09/28)

As part of a medicinal chemistry program, we adapted known synthetic methods for the late-stage diversification of 2,4-substituted 7-azaindoles. The strengths and weaknesses of these strategies are discussed. In the course of this work, three optimized co

TETRACYCLIC CDK9 KINASE INHIBITORS

-

Paragraph 1139, (2015/09/22)

Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

-

Page/Page column 455, (2014/09/29)

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

CDK9 KINASE INHIBITORS

-

Paragraph 0617, (2014/09/30)

Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES

-

Page/Page column 32, (2011/11/30)

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.

NOVEL COMPOUNDS

-

Page/Page column 42; 90, (2009/01/20)

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 480423-17-4